HTA Quarterly Archive

HTA Quarterly

Spring 2020

In this issue, our editors examine the patient voice and HTA, updates to the ICER and NICE frameworks, and the changing healthcare landscape in India with the adoption of their own HTA.
Read issue

HTA Quarterly

Fall 2019

In this issue, our editors examine cost-effectiveness assessments for innovative but high-cost treatments, market access for cell and gene therapies in key European countries, and newest joint HTA assessments, FINOSE.
Read issue

HTA Quarterly

Summer 2019

In this issue, we review HTA frameworks for next-gen sequencing in precision oncology, how HTAs review tumor-agnostic therapies, and the rise of complex technologies and their reimbursement landscape. Read our special feature, Hot Topic, on the changes in France’s healthcare system on medicinal products.
Read issue

HTA Quarterly

Spring 2019

In this issue, we examine the impact of the 21st Century Cures Act on stakeholders in the United States, explore the proposed rule from the Centers for Medicare & Medicaid Services on managed care value-based formulary decisions, and consider how patient input can help influence drug development.
Read issue

HTA Quarterly

Winter 2019

In this issue, we take a closer look at the utilization of “multiple criteria decision analysis” (MCDA) in health technology appraisals, newer therapies for Cystic Fibrosis, and the regulatory pathways and complexity of health technology assessment (HTA) evidentiary hurdles for new diabetes drugs, devices, and combination technologies.
Read issue

HTA Quarterly

Fall 2018

We examine wearable technology and big data, valuing CAR-T therapies, and a look at Catalonia and the region's autonomous healthcare market.
Read issue

HTA Quarterly

Late Summer 2018

We examine the world's second largest pharmaceuticals market as Japan shifts from a traditional reimbursement assessment. We look at new therapies for Tardive Dyskinesea. We also review Taiwan's Center for Drug Evaluation on its 10 year anniversary.
Read issue

HTA Quarterly

Summer 2018

We take a look at whether value frameworks are the path to implementing value-based pricing, the EMA's move out of the United Kingdom, and look at the health policy trends in Canada from InnomarLive.
Read issue

HTA Quarterly 

Spring 2018

We examine oncology appraisal differences between NICE and SMC, market access for cell and gene therapies, and managed entry agreements.
Read issue

HTA QUarterly

Late Summer 2017

We examine medical nutrition reimbursement, severe asthma therapies, and brazil's healthcare market.
Read issue

HTA QUARTERLY

Summer 2017

We take a look at patient input into HTA decisions in 4 countries, examining new therapies for Duchenne Muscular Dystrophy, and understanding the Colombian universal healthcare model.
Read issue

HTA QUARTERLY

Spring 2017

We examine the process to appeal unfavorable NICE decisions, provide insights on immunotherapy coverage and reimbursement, and take a deeper look at global value dossiers.
Read issue

HTA Quarterly

Winter 2017

We examine indication-specific pricing in Europe and in the US, approved therapies for multiple myeloma, and take a closer look at Portugal's HTA body, SiNATS.
Read issue

HTA Quarterly

Fall 2016

We examine rapid access in the US, UK, and France, targeted therapies for psoriasis and psoriatic arthritis, and explore Singapore's highly efficient healthcare system.
Read issue

Our Editors

EDITOR-IN-CHIEF

Kellie Meyer, PharmD, MPH

Vice President, Global Health Economics & Outcomes Research (GHEOR)
Meet Dr. Meyer

MANAGING EDITOR

Kimberly Riggs, MPH

Director, Global Health Economics & Outcomes Research (GHEOR)

 

Meet Ms. Riggs
Kimberly Riggs

Editorial Board

  • Josep Darba, PhD  Professor | Department of Economics | University of Barcelona | Spain
  • George Papadopoulos, BSc(Hons), GradDipEpi  President | Emerald Corporate Group | Australia
  • Ken Redekop, PhD  Associate Professor I Erasmus University I The Netherlands
  • Eldon Spackman, BA, MA, PhD  Assistant Professor | Community Health Sciences | University of Calgary | Canada
  • Keith Tolley, BA, MPhil Director | Tolley Health Economics | United Kingdom
  • Thomas Mittendorf, MSc, PhD  Managing Director | Xcenda GmbH | Germany
  • Trent McLaughlin, BSc(Pharm), PhD  Vice President, Real-World Evidence | Xcenda | United States
  • Michael Eaddy, PharmD, PhD  Vice President, Scientific Consulting | Xcenda | United States
  • Jay Jackson, PharmD, MPH  Senior Vice President, Consulting Services | Xcenda | United States